Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

CT-7439 is under development for the treatment of solid tumors including breast cancer, ovarian cancer and Ewing's Sarcoma. It acts by targeting cyclin dependent kinase 12 and 13 (CDK12 and 13). It is ...

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

TAS-0728 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Endometrial Cancer.

BLB-101 is under clinical development by Blue Lake Biotechnology and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Ligufalimab is under clinical development by Akeso and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Solid Tumor.

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...

PTS-500 is under clinical development by Gongwin Biopharm and currently in Phase II for Non-Small Cell Lung Cancer.

HMPL-306 is under clinical development by Hutchison MediPharma and currently in Phase I for Myeloproliferative Disorders.